-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $242

Benzinga·04/07/2026 18:13:50
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $204 to $242.